Companies › Cocrystal Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CDI-988 Norovirus antiviral | – | Phase 1 | Norovirus | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07198139 | CDI-988 | Phase 1 | Norovirus | Infectious disease | Sep 2026 |
Cash of $2m on 2026-06-30; operating cash outflow about $10m a year; runway about 3 months at that burn, to Sep 2026
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.